Paper - WANFANG MED ONLINE

You Position: Home > Paper

Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors

( views:96, downloads:24 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 4

DOI:: 10.3760/cma.j.issn.0366-6999.20120912

Key Word:: allogeneic;hematopoietic stem cell transplantation;chronic myeloid leukemia;tyrosine kinase inhibitors;imatinib

Abstract： The approval of imatinib in 2001 has changed the landscape of CML management.1-3 With its excellent efficacy in the International Randomized Study of Interferon and STI571 (IRIS),imatinib has become the standard of care for newly diagnosed patients.This change challenges the previous role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CML treatment.However,allo-HSCT still plays an important role in the treatment of CML patients because of the following reasons:(1) up to one-third of patients in the first chronic phase (CP1) of CML (CML-CP1) are resistant to or intolerant of imatinib therapy;4,5 (2)patients with the T315I mutation are highly resistant to all tyrosine kinase inhibitors (TKIs);(3) pediatric and young patients with an identical sibling donor have a strong willingness to be cured;(4) patients with advanced disease have poor response to TKIs;and (5) the outcomes of HSCT have improved in recent years.So in this era,the indication was more complex and stratified in more detail,based on weighing the disease related risk and SCT related risk.

Reference

[1]XU Lan-ping,HUANG Xiao-jun.Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group[J].2011,(16).
[2]Jiang Q,Liu KY,Chen SS,etc.Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.[J].2011,117(11).
[3]D-W, Kim,Y-J, Chung,S, Lee,etc.Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.[J].2004,18(11).
[4]H, Castro-Malaspina,G, Schaison,J, Briere,etc.Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors.[J].1983,52(4).
[5]Roy L,Corm S,Silver RT,etc.Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.[J].2008,22(6).
[6]Santini V,Breccia M,Gozzini A,etc.Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.[J].2011,86(6).
[7]Susan, O'Brien,Ellin, Berman,Hossein, Borghaei,etc.NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.[J].2009,7(9).
[8]Isoyama K,Miyamura K,Nagamura F,etc.Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis.[J].2008,42(4).
[9]Hochhaus A,Deininger M,Jabbour E.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.[J].2011,25(2).
[10]Apperley J,Ruutu T,Corradini P,etc.Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Tran[J].2006,91(4).
[11]Thongnoppakhun,W.,Wongboonma,W.,Auewarakul,C.U..BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-na?ve and -exposed Southeast Asian chronic myeloid leukemia patients[J].2012,92(2).
[12]Velev N,Cortes J,Champlin R,etc.Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.[J].2010,116(15).
[13]Kaeda JS,Branford S,Wehrle E,etc.Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).[J].2010,116(19).
[14]Tanizawa A,Kurosawa H,Yoshimi A,etc.Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program.[J].2010,16(2).
[15]Neudorf,S.M.,Andolina,J.R.,Corey,S.J..How I treat childhood CML[J].2012,119(8).
[16]A, Shimoni,M, Leiba,M, Schleuning,etc.Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive [J].2009,23(1).
[17]O'Brien S,Jones RB,Cortes J,etc.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.[J].2011,117(13).
[18]Catherine C, Smith,Neil P, Shah.Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.[J].2011,2011.
[19]Gnani A,Iacobucci I,Castagnetti F,etc.Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.[J].2009,114(10).
[20]Olavarria E,Pavlu J,Reid AG,etc.European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.[J].2008,112(12).
[21]Urbano Ispizua A,Baldomero H,Gratwohl A,etc.Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey.[J].2004,34(10).
[22]Zheng Y,Xie W,Lin M,etc.Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.[J].2011,35(10).
[23]HUANG XIAO-JUN,XU LAN-PING,LIU KAI-YAN.HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase[J].2008,40(6).
[24]Liu KY,Gao ZY,Liu DH,etc.Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.[J].2006,38(4).